WHO has advised against the use of antibody therapies sotrovimab and casirivimab-imdevimab against COVID-19
Image Credit: Forbes
New guidance from the World Health Organisation strongly advises against using the antibody therapies sotrovimab and casirivimab-imdevimab to treat patients with COVID-19. This guidance, published in the British Medical Journal, replaces previous conditional recommendations for the use of these drugs. It's based on emerging evidence that they're not likely to work against current COVID variants such as omicron.